Option chain shows key data for Bitcoin Depot's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Bitcoin Depot.

Bitcoin Depot (NASDAQ:BTM) Stock, Option Chain

Bitcoin Depot

Bitcoin Depot Inc owns and operates the largest network of BTMs across North America where customers can buy and sell Bitcoin. Bitcoin Depot helps power the digital economy for users of cash. It has locations across the U.S. and Canada at, among others, the following types of retailers: Convenience Stores and Gas Station Chains, Pharmacies and Grocers and Mall Operators.

Google Parent Alphabet

News

Short Ideas

Insider Trades

Pre-Market Outlook

GOOG

GOOGL

Alphabet, Goldman Sachs And 2 Other Stocks Insiders Are Selling

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABBV

AEHR

AKAN

BCAN

BCLI

CIFR

COOT

CYTO

CZOO

EGOX

ESPR

FLGC

FRGE

GDRX

IVVD

JWEL

LABP

LASE

LCID

LDOS

LICN

LICY

LPRO

MASI

MLGO

MSTR

NKTX

OCGN

OKYO

OTRK

SGMT

SINT

SLRX

SOND

STIM

SWVL

URGN

VMEO

XTLB

Shares of  Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Advanced Environmental Recycling Technologies

AERT

AUVI

BETS

CRGE

EVOK

FLXS

FTFT

GRFS

GRPN

INPX

LAES

MAIA

MARA

MARK

MDAI

Airspan Networks Holdings Inc. Common Stock

MIMO

MNTS

NUKK

NVVE

RDZN

SOLO

VCIG

VLCN

VVPR

WKEY

ZJYL

Shares of Wipro Limited (NYSE: WIT) rose sharply during Friday’s session after the company reported third-quarter financial results, issued guidance and declared an interim dividend.

Wipro shares jumped 16.7% to $6.27 on Friday.

Why Wipro Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Bitcoin Depot Inc. - Class A Common Stock

Bitcoin Depot Inc

Bytom

Biote Corp

B of A Securities analyst Jason Kupferberg maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Buy and raises the price target from $50 to $74.

Price Target

Analyst Ratings

AFRM

B of A Securities Maintains Buy on Affirm Holdings, Raises Price Target to $74

WIIM

ROST

Ross Stores shares are trading higher after the company reported better-than-expected Q3 EPS results.

IES Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IESC#NASDAQ">IESC</a>) reported quarterly earnings of $2.79 per share. This is a 60.34 percent increase over earnings of $1.74 per share from the same period last year. The company reported $776.00 million in sales this quarter. This is a 19.57 percent increase over sales of $649.00 million the same period last year.

Earnings

IESC

IES Hldgs Q4 Adj EPS $2.79 Up From $1.74 YoY, Sales $776.00M Up From $649.00M YoY

B of A Securities maintains Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) with a Neutral and raises the price target from $25 to $28.

B of A Securities Maintains Neutral on Gap, Raises Price Target to $28

Leerink Partners analyst David Risinger upgrades AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) from Market Perform to Outperform and announces $206 price target.

Upgrades

Leerink Partners Upgrades AbbVie to Outperform, Announces $206 Price Target

B of A Securities analyst Tyler DuPont initiates coverage on Kyndryl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) with a Buy rating and announces Price Target of $40.

Initiation

B of A Securities Initiates Coverage On Kyndryl Hldgs with Buy Rating, Announces Price Target of $40

INTU

Intuit shares are trading lower after the company reported Q2 financial results. The company issued Q2 adjusted EPS and revenue guidance below analyst estimates.

B of A Securities analyst Tyler DuPont initiates coverage on Endava (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAVA#NYSE">DAVA</a>) with a Neutral rating and announces Price Target of $29.

DAVA

B of A Securities Initiates Coverage On Endava with Neutral Rating, Announces Price Target of $29

Empire Petroleum Increases Revolver Loan Facility With Equity Bank To $20M In Support Of Strategic Growth Initiatives; Currently, Empire Has Approximately $8.4M Borrowed On The $20.0 Million Facility

JP Morgan analyst Bennett Moore initiates coverage on Carpenter Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) with a Overweight rating and announces Price Target of $220.

JP Morgan Initiates Coverage On Carpenter Tech with Overweight Rating, Announces Price Target of $220

JMP Securities analyst Matthew Carletti maintains Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) with a Market Outperform and raises the price target from $25 to $35.

HIPO

JMP Securities Maintains Market Outperform on Hippo Holdings, Raises Price Target to $35

B of A Securities analyst Sachin Salgaonkar downgrades Grab Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) from Buy to Underperform and maintains the price target from $4.9 to $4.9.

Downgrades

GRAB

B of A Securities Downgrades Grab Holdings to Underperform, Maintains Price Target to $4.9

APi Group Corporation Says Kevin Krumm, Chief Financial Officer, Will Step Down From His Role On December 13; David Jackola, Current Chief Financial Officer And Vice President Of Transformation At APi International, Will Assume The Role Of Interim Chief Financial Officer

JMP Securities analyst Nicholas Jones maintains CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) with a Market Outperform and raises the price target from $41 to $46.

CARG

JMP Securities Maintains Market Outperform on CarGurus, Raises Price Target to $46

Baird analyst Shrenik Kothari upgrades Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) from Neutral to Outperform and raises the price target from $95 to $135.

ESTC

Baird Upgrades Elastic to Outperform, Raises Price Target to $135

<ul>
<li>In October 2020, YmAbs announced a plan to commercialize Omburtamab but failed to get FDA approval for it.</li>
<li>Despite lacking sufficient evidence and not meeting the FDA's requirements, Y-mAbs submitted an application to commercialize Omburtamab.&nbsp;</li>
<li>In October 2022, the FDA's committee unanimously voted against granting the license for Omburtamab.&nbsp;</li>
<li>The market reacted sharply to the news, with Y-mAbs stock plunging to a historic low of $3.15 by the end of October 2022.</li>
<li>Following the sudden stock price drop, in January 2023, shareholders sued the company.</li>
<li>Y-mAbs has agreed to a $19.65 million settlement with shareholders to resolve the lawsuit. Affected investors can now <a href="https://11thestate.com/cases/ymabs-investor-settlement">file a claim</a> to receive their payment.</li>
</ul>
<h3 class="wp-block-heading has-medium-font-size">Overview</h3>
Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) stock peaked at $54.1 in late 2020, fueled by high hopes for its cancer treatment, Omburtamab. However, the FDA's 2020 Refusal to File and subsequent Complete Response Letter citing missing efficacy data undermined its progress, leading to a 71.65% stock drop by October 2022. After that, in January 2023, investors filed a class-action lawsuit, claiming that the company misled them about Omburtamab's approval chances. Recently, Y-mAbs ultimately reached a $19.65 million settlement with the affected shareholders to resolve this scandal.&nbsp;

<h3 class="wp-block-heading has-medium-font-size">Omburtamab &#8211; The Achilles' Heel For Y-mAbs Ambitions</h3>

Y-mAbs Therapeutics, founded in 2015, quickly positioned itself as a promising player in the oncology field, focusing on developing novel antibody-based therapies.
Its flagship drug, Omburtamab, was designed to target central nervous system and leptomeningeal metastases in pediatric neuroblastoma patients.&nbsp;
Y-mAbs aimed to commercialize Omburtamab, promoting it as a breakthrough treatment for children suffering from one of the deadliest forms of cancer.
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<cite>"We are excited to share these results that significantly broaden the potential reach of Omburtamab, which would be addressing a clear unmet medical need. The results pave the way for our multicenter phase 2 study in DIPG later this year, where we expect to give up to three repeated doses of Omburtamab," stated Thomas Gad, founder, Chairman and President.</cite></blockquote>
After its IPO, Y-mAbs stock surged 58% in 2020, peaking at $54 as investors expressed strong confidence in its future plans.
Then, on October 3, 2022, Y-mAbs <a href="https://ir.ymabs.com/news-releases/news-release-details/y-mabs-announces-pivotal-data-omburtamab">claimed</a> that the research data for Omburtamab trials was satisfactory. They remained confident that they would meet the additional data requirements requested by the FDA.
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<cite>"The disease burden these patients and their families are facing represents a significant unmet medical need, which we hope to be able to address with OMBLASTYS after our PDUFA date on November 30, 2022."</cite></blockquote>
However, despite high claims from Gad, Y-mAbs couldn't convince the FDA to start commercial production of Omburtmab.

<h3 class="wp-block-heading has-medium-font-size">The FDA Shatters The Omburtamab Venture</h3>
The FDA dashed any remaining hopes for Omburtamab&#8217;s viability when it issued a Complete Response Letter.
In response, Thomas Gad said: 
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">
<cite>"We are disappointed by the CRL but not surprised based on the outcome of the ODAC meeting on October 28. We want to express our gratitude to all the patients, their families, and investigators who have participated in our clinical trials and advocated for the advancement of Omburtamab."</cite></blockquote>
The fallout from Omburtamab became even more devastating with the FDA&#8217;s detailed response. Y-mAbs failed to address the FDA's concerns over the lack of viability and efficacy in the patient trial data, which were required before submitting the BLA in March 2022. This oversight complicated the situation further as the company neglected to meet the FDA&#8217;s demands for more diversified data and larger testing volumes.
After that, on October 5, 2020, Y-mAbs provided an update on Omburtamab, downplaying any significant obstacles to receiving the BLA.&nbsp;
"We will request a Type A meeting with the FDA as soon as possible, and plan to work in close dialog with the Agency to amend the BLA with the goal of resubmitting the BLA before the end of 2020" stated the press release from Y-mAbs.
However, the company couldn't convince the FDA through a series of meetings and resubmissions.
Investors' confidence in Y-mAbs suffered a serious blow in October 2022 when the FDA, after months of review, ultimately <a href="https://ir.ymabs.com/news-releases/news-release-details/y-mabs-announces-complete-response-letter-omburtamab-biologics">rejected</a> the company&#8217;s Biologics License Application for Omburtamab.
This rejection revealed that the FDA had raised substantial concerns regarding the drug's efficacy, particularly due to gaps in the data used to support its intended application in treating CNS/leptomeningeal metastases.
The day after the FDA revelations, Y-mAbs stock dropped 19.16%, eventually hitting a historic low of $3.10.
<figure class="wp-block-image is-resized"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXfYWbefph28Jr40WvJHQmhs1_dLhpfkW_flTnHFf3fdm6_AdGwTFg112rNGhiteRLX2Lhn0mR_yGJ_Hlw7O0JY3dOETNalwF69FJOpMs1tvFrEGYgVSCmHtsgSgo1WDwD4UOTEBPA?key=uQ4PIB59WNO670EWBObXCpjS" alt="" style="width:624px" /><figcaption class="wp-element-caption">Y-mAbs Stock Price Falls &#8211; October 26, 2022</figcaption></figure>
After that, on January 18, 2023, investors sued Y-mAbs for misleading about the FDA approval.
Resolving The Case
To resolve the lawsuit from investors, Y-mAbs has agreed to a cash settlement of $19.65 million. If you invested in Y-mAbs, you may be eligible to <a href="https://11thestate.com/cases/ymabs-investor-settlement">claim a portion</a> of this settlement to recover your losses.
After the setback with Omburtamab, Y-mAbs shifted its focus to &#8220;Danyelza,&#8221; an FDA-approved drug as of 2023, aiming to stabilize operations. The company implemented a restructuring plan, cutting expenses by 28% and its salesforce by 35%, while projecting $60–65 million in net revenue from Danyelza sales. While these efforts improved its financial standing, the recovery relied more on cost-cutting than significant revenue growth. The stock, however, never recovered to its 2020 peak of $54 and, by November 2024, had fallen nearly 80%, trading at just $11.

Biotech

General

YMAB

Y-mAbs' Omburtamab Failure: The Critical Turning Point And $19.65M Shareholder Settlement

This decision follows the receipt of a "deficiencies preclude discussion" letter from the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for Zynquista&#x2122; (sotagliflozin) as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes and chronic kidney disease (CKD). The letter noted deficiencies with the application that preclude discussion of labeling and/or post-marketing requirements and commitments at this time.
"While this decision was not made lightly, it reflects our commitment to make prudent business decisions that enhance value across our portfolio and deliver on our Lead to Succeed strategy," said Mike Exton, Ph.D., Lexicon's chief executive officer and director. "We see significant potential in our strong pipeline of R&amp;D opportunities, and we will focus our resources on programs with the potential for the greatest impact. We are confident that by carefully selecting therapeutic areas where we are the first and only therapy in class, and focusing our R&amp;D efforts where there are significant needs, we can deliver innovations that will meaningfully benefit patients while simultaneously positioning Lexicon to fully realize future growth opportunities."

LXRX

Lexicon Pharmaceuticals Says Company Has Made Strategic Decision To Eliminate Its Commercial Operations And Rationalize Resources Across All Functions In Order To Preserve Cash And Focus Its Resources On Advancing Promising Clinical Development Pipeline Following Regulatory Update From FDA; Efforts Expected To Reduce 2025 Operating Costs By $100M

Baird analyst Jeffrey Meuler upgrades Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) from Neutral to Outperform and maintains the price target from $140 to $140.

BFAM

Baird Upgrades Bright Horizons Family to Outperform, Maintains Price Target to $140

Baird analyst Jeffrey Meuler upgrades KinderCare Learning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) from Neutral to Outperform and maintains the price target from $30 to $30.

Baird Upgrades KinderCare Learning to Outperform, Maintains Price Target to $30

The Germany commercial property market "<a href="https://open.substack.com/pub/europeancapitalinsights/p/germanys-commercial-real-estate-market?r=3nmatg&amp;utm_campaign=post&amp;utm_medium=web">remains a source of elevated risk</a>," one that financial regulators are monitoring closely after a rapid succession of interest rate increases hit property values.
"The financial system is facing acute challenges due to geopolitical tensions and a weak economy," Michael Theurer, an Executive Board member of the Deutsche Bundesbank, <a target="_blank" rel="noreferrer noopener" href="https://www.bundesbank.de/en/press/speeches/statement-on-the-publication-of-the-financial-stability-review-2024-on-21-november-2024-944842">said </a>on Thursday. "This is making supervisors more vigilant, particularly with regard to the commercial real estate sector."
The European Central Bank (ECB) hiked interest rates in 2022 as the eurozone witnessed an "<a href="https://www.ecb.europa.eu/press/blog/date/2024/html/ecb.blog240311~968c707650.en.html" target="_blank" rel="noreferrer noopener">extraordinary surge</a>" in inflation fueled by the energy crisis from Russia's invasion of Ukraine. Even though the ECB began lowering rates this year, cutting from 4.5% to 3.4%, German commercial property developers remain at risk, according to the Bundesbank.
"Higher interest rates and energy prices caused a number of risks to emerge," Theurer said. &#8220;Real estate prices fell and credit risk rose."
<figure class="wp-block-image is-resized"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F22ac4199-cbac-4639-8efa-4a64abe78cf8_566x312.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F22ac4199-cbac-4639-8efa-4a64abe78cf8_566x312.png" alt="" style="width:624px" /></a><figcaption class="wp-element-caption">Source: <a target="_blank" rel="noreferrer noopener" href="https://www.bundesbank.de/en/press/speeches/statement-on-the-publication-of-the-financial-stability-review-2024-on-21-november-2024-944842#tar-1">Bundesbank</a></figcaption></figure>
The <a target="_blank" rel="noreferrer noopener" href="https://www.boerse-frankfurt.de/indices/daxsubsector-all-real-estate-performance">DAX subsector All Real Estate</a> has declined to its lowest level since August 16. It traded at €159.11 at CET 11:30 today. The country's biggest landlord by market volume, Vonovia <a target="_blank" rel="noreferrer noopener" href="https://www.reuters.com/markets/companies/VNAn.DE">(VNAn.DE)</a>, dropped <a target="_blank" rel="noreferrer noopener" href="https://www.boerse-frankfurt.de/indices/daxsubsector-all-real-estate-performance/constituents">44% during the past three years</a>, despite rising 16% in the past year.&nbsp;
<h3 class="wp-block-heading">German Financial System ‘Weathered' High Rates</h3>
The German financial system has "weathered the phase of exceptionally strong rises in interest rates well overall," he said. "The resilience of the banking system is adequate thanks to high capital reserves. Vulnerabilities are declining, but only gradually."&nbsp;
But conditions in the commercial property market are influencing German open-end retail real estate funds, according to the Bundesbank.&nbsp;
"As a rule, such funds have high liquidity risk," Theurer said. "Most recently they have seen net outflows, with investors anticipating higher returns on alternative investments. This could accentuate negative developments in commercial real estate."
<figure class="wp-block-image is-resized"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F76ac9770-ac19-4188-a738-efff1cfae3fa_577x313.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F76ac9770-ac19-4188-a738-efff1cfae3fa_577x313.png" alt="" style="width:624px" /></a><figcaption class="wp-element-caption">Source: Bundesbank</figcaption></figure>
Given the overall risk, <a target="_blank" rel="noreferrer noopener" href="https://www.bnnbloomberg.ca/business/company-news/2024/11/21/bundesbank-vigilant-on-commercial-property-in-weak-economy/">a package of additional capital buffers</a> that regulators ordered banks to build up in 2022 "remains appropriate."&nbsp;
<h3 class="wp-block-heading">German Economic ‘Malaise' Shows No Signs Of Improving</h3>
In the meantime, Germany's "economic malaise" showed no signs of improving, according to a <a target="_blank" rel="noreferrer noopener" href="https://www.pmi.spglobal.com/Public/Home/PressRelease/501260501cab4cb382c5ec521210a125">survey</a> compiled by S&amp;P Global. The latest HCOB ‘flash' PMI&#xAE; survey showed business activity in November falling for the fifth month running and at the quickest rate since February.
The first decrease in services activity for nine months compounded a "sustained weakness in manufacturing production," the survey said today. Weaker demand for goods and services led to further job losses during the year's penultimate month, it said.&nbsp;
"Until recently, the German economy was stabilized somewhat by the service sector, which was making up for the steep decline in manufacturing," Cyrus de la Rubia, Chief Economist at Hamburg Commercial Bank, said. "Not anymore,"
As a result, German gross domestic product (GDP) contracted an annual 0.3% in Q3, Federal Statistical Office (Destatis) <a target="_blank" rel="noreferrer noopener" href="https://www.destatis.de/EN/Press/2024/11/PE24_438_811.html">data showed</a> today. GDP rose quarterly by 0.1% in Q3, though growth was revised 0.1 percentage points lower from<a target="_blank" rel="noreferrer noopener" href="https://www.destatis.de/EN/Press/2024/10/PE24_408_811.html"> its October 30</a> forecast.
<figure class="wp-block-image is-resized"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2740fa69-29bf-41ee-b71b-4d6542df9722_1151x291.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2740fa69-29bf-41ee-b71b-4d6542df9722_1151x291.png" alt="" style="width:624px" /></a><figcaption class="wp-element-caption">Source: <a target="_blank" rel="noreferrer noopener" href="https://www.destatis.de/EN/Press/2024/11/PE24_438_811.html">Destatis</a></figcaption></figure>
<h3 class="wp-block-heading">German Economy Hurt By Domestic Political Turmoil</h3>
While German officials regularly point to trade tensions and geopolitical risks, domestic political turmoil has weighed on economic growth. Political uncertainty since the announcement of snap elections "isn&#8217;t helping," Rubia said.&nbsp;
Chancellor Olaf Scholz's<a target="_blank" rel="noreferrer noopener" href="https://europeancapitalinsights.substack.com/p/german-coalition-collapse-leaves"> coalition government collapsed </a>earlier this month after weeks of government squabbling about the ailing economy. Until early elections on <a target="_blank" rel="noreferrer noopener" href="https://www.cnbc.com/2024/11/12/germany-sets-election-date-for-february-after-ruling-coalition-collapse.html?msockid=2d606d947ad16d223dd779537bd86c37">February 23</a>, the European nation will be politically rudderless.&nbsp;&nbsp;
Amid the weak German economy, corporate insolvencies have "risen significantly," according to the Bundesbank. Insolvencies among trading companies are particularly high – totaling over €7 billion as of the end of June 2024.
<figure class="wp-block-image is-resized"><a href="https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F05c53b75-7b3a-4255-81d9-fb950e07e161_571x317.png" target="_blank" rel="noreferrer noopener"><img decoding="async" src="https://substackcdn.com/image/fetch/w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F05c53b75-7b3a-4255-81d9-fb950e07e161_571x317.png" alt="" style="width:624px" /></a><figcaption class="wp-element-caption">Source: <a target="_blank" rel="noreferrer noopener" href="https://www.bundesbank.de/en/press/speeches/statement-on-the-publication-of-the-financial-stability-review-2024-on-21-november-2024-944842">Bundesbank</a></figcaption></figure>
Insolvency claims against the services sector and against the real estate activities sector are somewhat lower. They are nevertheless "substantial"&nbsp;at €5.5 billion and roughly €6.5 billion, respectively, according to the Bundesbank.&nbsp;
"The path ahead is an arduous one," Theurer said. "Geopolitical tensions continue to harbor risks to the future stability of the financial system."
Disclaimer
Any opinions expressed in this article are not to be considered investment advice and are solely those of the authors. European Capital Insights is not responsible for any financial decisions made based on the contents of this article. Readers may use this article for information and educational purposes only.
This article is from an unpaid external contributor. It does not represent Benzinga&#8217;s reporting and has not been edited for content&nbsp;or&nbsp;accuracy.

Eurozone

Economics

German Commercial Property Market Is 'Source Of Elevated Risk'

"During the third quarter, we made significant strides in expanding our Bitcoin ATM network while working to optimize existing machines for greater...

Bitcoin Depot reports Q3 revenue $135.5M, consensus $135.81M

Bitcoin Depot reports Q3 results

Bitcoin Depot Inc. (BTM) Q3 2024 Earnings Call Transcript

Bitcoin Depot Inc. ( ($BTM) ) has released its Q3 earnings. Here is a breakdown of the information Bitcoin Depot Inc. presented to its investors. B...

Bitcoin Depot Inc. Reports Strong Net Income Growth

In a report released today, Michael Grondahl from Northland Securities maintained a Hold rating on Bitcoin Depot (BTM – Research Report), with a pr...

Bitcoin Depot (BTM) Gets a Hold from Northland Securities

Mike Colonnese, an analyst from H.C. Wainwright, reiterated the Buy rating on Bitcoin Depot (BTM – Research Report). The associated price target is...

Bitcoin Depot's Strong Performance and Strategic Growth Drive Buy Rating

An update from Bitcoin Depot ( ($BTM) ) is now available. Bitcoin Depot, Inc. announced the resignation of their CFO, Glen Leibowitz, effective Nov...

Bitcoin Depot CFO Resigns; COO Steps In Temporarily

In a regulatory filing, Bitcoin Depot (BTM) disclosed that, on November 18, the company announced that Glen Leibowitz has resigned from his role as...

Bitcoin Depot announces resignation of CFO Glen Leibowitz

Bitcoin Depot: Recent Surge Is Tied To Bitcoin's Sympathy Play

The company may offer shares of Class A common stock, shares of preferred stock, warrants, and units consisting of any combination of Class A commo...

Bitcoin Depot files $25M mixed securities shelf

BTMWW

Press Releases

Bitcoin Depot Announces Sale of 200 Additional Kiosks to Sopris Capital Through Profit-Sharing Program

Gateway Group Announces Preliminary Sponsors and Additional Presenting Companies for September Gateway Conference

Bitcoin Depot Exceeds Goal Deploying of 8,000 Bitcoin ATMs Five Months Ahead of Schedule

Bitcoin Depot Schedules Second Quarter 2024 Conference Call for Tuesday, August 13th at 10:00 am ET

Bitcoin Depot Expands BDCheckout Program to Six New States

Bitcoin Depot Reports Second Quarter 2024 Financial Results

Bitcoin Depot to Present at the 2024 Gateway Conference on September 5th, 2024

2024 Gateway Conference to Feature AI, Blockchain, and Digital Infrastructure Track on September 5th

Bitcoin Depot Schedules Third Quarter 2024 Conference Call for Wednesday, November 13th at 10:00 am ET

Comments

Bitcoin Depot

Bitcoin Depot (BTM) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga